2012
DOI: 10.1186/1755-1536-5-2 View full text |Buy / Rent full text
|
|

Abstract: CCL18, a chemokine with no known receptor, has been implicated in several fibrotic pulmonary diseases associated with T-lymphocyte infiltration. It has been hypothesized that CCL18 may act through CCR6. Gene delivery of human CCL18 to the lungs of wild-type mice induced pulmonary infiltration of T-lymphocytes, less than 5% of which expressed CCR6. In the lungs of CCR6-deficient mice, CCL18-driven infiltration of T-lymphocytes was attenuated but not fully abrogated. It was concluded that CCR6 is not necessary f… Show more

Help me understand this report

Search citation statements

Order By: Relevance
Select...
1
1
1
1
0
4
0

Year Published

2013
2013
2019
2019

Publication Types

Select...
3
1

Relationship

0
4

Authors

Journals

0
4
0
Order By: Relevance
“…In contrast, gene delivery of human CCL18 which has no known receptor, to the lungs of wild type (WT) mice induced pulmonary infiltration of T lymphocytes, but only less than 5% of the population had expressed CCR6. In the lungs of CCR6 deficient mice, CCL18-driven T lymphocyte trafficking was attenuated but not fully abrogated, concluding that CCR6 was not necessary for CCL18 -induced changes in mice in vivo and that CCR6 is not the main functional receptor for CCL18 in this model [27].…”
Section: Lungmentioning
Create an account to read the remaining citation statements from this report. You will also get access to:
  • Search over 1.2b+ citation statments to see what is being said about any topic in the research literature
  • Advanced Search to find publications that support or contrast your research
  • Citation reports and visualizations to easily see what publications are saying about each other
  • Browser extension to see Smart Citations wherever you read research
  • Dashboards to evaluate and keep track of groups of publications
  • Alerts to stay on top of citations as they happen
  • Automated reference checks to make sure you are citing reliable research in your manuscripts
  • 7 day free preview of our premium features.

Trusted by researchers and organizations around the world

Over 130,000 students researchers, and industry experts at use scite

See what students are saying

rupbmjkragerfmgwileyiopcupepmcmbcthiemesagefrontiersapsiucrarxivemeralduhksmucshluniversity-of-gavle
“…In contrast, gene delivery of human CCL18 which has no known receptor, to the lungs of wild type (WT) mice induced pulmonary infiltration of T lymphocytes, but only less than 5% of the population had expressed CCR6. In the lungs of CCR6 deficient mice, CCL18-driven T lymphocyte trafficking was attenuated but not fully abrogated, concluding that CCR6 was not necessary for CCL18 -induced changes in mice in vivo and that CCR6 is not the main functional receptor for CCL18 in this model [27].…”
Section: Lungmentioning
“…Although our study only confirms the clinical significance of serum CCL18 in patients with LSCC, CCL18 is also reported to be an efficient molecular target in TME to repress cancer progression. In one respect, CCL18 in TME binds to its receptors (PITPNM3 12, CCR6 28 and CCR8 29-31) on the membrane of tumor cells, activates multiple carcinogenesis associated signaling pathways including NF-κB, PI3K/Akt, Wnt/β-catenin and mTOR etc, which in turn accelerates the progression of diverse human cancers including head and neck cancer 13, 14. On the other hand, CCL18 as a secreted cytokine also remodels TME to promote cancer progression.…”
Section: Discussionmentioning
“…In the lungs of CCR6 knockout mice, CCL18-driven T lymphocyte trafficking was reduced but not completely halted. These observations, made in vivo in mice, concluded that CCR6 was not required for CCL18-induced changes, and that CCR6 is not the principal receptor for CCL18 in this animal model [ 27 ].…”
Section: Ccr6 and Ccl20 In Health And Diseasementioning